Beijing Hotgen Biotech Hits Day Low of CNY 79 Amid Price Pressure

Beijing Hotgen Biotech Co., Ltd. experienced a significant decline in its stock performance today, with a drop of 5.62%. The stock reached an intraday low of CNY 79.00, reflecting ongoing challenges within the company. Over the past week, the stock has decreased by 5.89%, and its performance over the last month shows a substantial decline of 27.81%. In the context of the broader market, the China Shanghai Composite index has shown a slight gain of 0.43% today, contrasting sharply with Beijing Hotgen's performance. Year-to-date, the stock has fallen by 50%, while the Shanghai Composite has increased by 2.68%. Financial metrics indicate a concerning trend for Beijing Hotgen, with net sales declining by 4.41% and a net profit of CNY -75.78 million, reflecting a growth rate of -58.81%. The company has reported negative results for the last 12 consecutive quarters, highlighting persistent difficulties. With a market capitalization of CNY 8,780 million, the company operates in the pharmaceuticals and biotechnology sector, but its financial indicators suggest a challenging environment ahead.